Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis
We performed a systematic review and meta-analysis of the correlation between cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab. Eligible studies included phase I, II and III trials of patients with solid tumors on cetuximab; describing events of skin rash and correlating skin rash with overall survival (OS), progression free survival (PFS) and/or overall response rate (ORR). Our search strategy yielded 409 potentially relevant citations on CETUXIMAB from Pubmed/Medline, CENTRAL Cochrane registry and ASCO meeting library. After exclusion of ineligible studies, a total of 13 clinical trials were considered eligible for the meta-analysis, including 4 phase III trials, 8 phase II trials and one phase I trial. The occurrence of cetuximab-induced rash in patients was highly associated with improvements in PFS (HR=0.74; 95% CI: 0.63-0.86, P<0.0002), OS (HR=0.60; 95% CI: 0.47-0.76, P<0.0001), and ORR (RR=1.51, 95% CI: 1.26-1.81, P<0.00001), as compared to patients without rash. Exploratory subgroup analysis showed no effect of tumor types on the RR of ORR. Our meta-analysis has demonstrated that cetuximab-induced rash is associated with a significantly improved OS, PFS and ORR. Cetuximab-induced skin rash may represent a prognostic factor in patients with advanced solid tumors..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
|---|---|
| Enthalten in: |
Critical reviews in oncology, hematology - 93(2015), 2, Seite 127-135 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdel-Rahman, Omar [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1016/j.critrevonc.2014.07.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1956865918 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1956865918 | ||
| 003 | DE-627 | ||
| 005 | 20230714142059.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.critrevonc.2014.07.005 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1956865918 | ||
| 035 | |a (DE-599)GBVOLC1956865918 | ||
| 035 | |a (PRQ)c953-c04cc543b075d798bb71dd62fca252c2993d0db946d77da3a18b3154a506691e0 | ||
| 035 | |a (KEY)0133835820150000093000200127correlationofcetuximabinducedskinrashandoutcomesof | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ZDB |
| 100 | 1 | |a Abdel-Rahman, Omar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a We performed a systematic review and meta-analysis of the correlation between cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab. Eligible studies included phase I, II and III trials of patients with solid tumors on cetuximab; describing events of skin rash and correlating skin rash with overall survival (OS), progression free survival (PFS) and/or overall response rate (ORR). Our search strategy yielded 409 potentially relevant citations on CETUXIMAB from Pubmed/Medline, CENTRAL Cochrane registry and ASCO meeting library. After exclusion of ineligible studies, a total of 13 clinical trials were considered eligible for the meta-analysis, including 4 phase III trials, 8 phase II trials and one phase I trial. The occurrence of cetuximab-induced rash in patients was highly associated with improvements in PFS (HR=0.74; 95% CI: 0.63-0.86, P<0.0002), OS (HR=0.60; 95% CI: 0.47-0.76, P<0.0001), and ORR (RR=1.51, 95% CI: 1.26-1.81, P<0.00001), as compared to patients without rash. Exploratory subgroup analysis showed no effect of tumor types on the RR of ORR. Our meta-analysis has demonstrated that cetuximab-induced rash is associated with a significantly improved OS, PFS and ORR. Cetuximab-induced skin rash may represent a prognostic factor in patients with advanced solid tumors. | ||
| 540 | |a Nutzungsrecht: Copyright © 2014 Elsevier Ireland Ltd. All rights reserved. | ||
| 650 | 4 | |a Carcinoma, Squamous Cell - diagnosis | |
| 650 | 4 | |a Head and Neck Neoplasms - drug therapy | |
| 650 | 4 | |a Exanthema - chemically induced | |
| 650 | 4 | |a Exanthema - diagnosis | |
| 650 | 4 | |a Head and Neck Neoplasms - diagnosis | |
| 650 | 4 | |a Colorectal Neoplasms - drug therapy | |
| 650 | 4 | |a Head and Neck Neoplasms - mortality | |
| 650 | 4 | |a Carcinoma, Non-Small-Cell Lung - drug therapy | |
| 650 | 4 | |a Colorectal Neoplasms - diagnosis | |
| 650 | 4 | |a Exanthema - pathology | |
| 650 | 4 | |a Carcinoma, Squamous Cell - mortality | |
| 650 | 4 | |a Receptor, Epidermal Growth Factor - antagonists & inhibitors | |
| 650 | 4 | |a Carcinoma, Non-Small-Cell Lung - pathology | |
| 650 | 4 | |a Colorectal Neoplasms - pathology | |
| 650 | 4 | |a Carcinoma, Non-Small-Cell Lung - diagnosis | |
| 650 | 4 | |a Carcinoma, Squamous Cell - drug therapy | |
| 650 | 4 | |a Carcinoma, Non-Small-Cell Lung - mortality | |
| 650 | 4 | |a Carcinoma, Squamous Cell - pathology | |
| 650 | 4 | |a Antineoplastic Agents - adverse effects | |
| 650 | 4 | |a Antibodies, Monoclonal, Humanized - adverse effects | |
| 650 | 4 | |a Head and Neck Neoplasms - pathology | |
| 650 | 4 | |a Receptor, Epidermal Growth Factor - genetics | |
| 650 | 4 | |a Colorectal Neoplasms - mortality | |
| 700 | 1 | |a Fouad, Mona |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Critical reviews in oncology, hematology |d Amsterdam : Elsevier, 1983 |g 93(2015), 2, Seite 127-135 |w (DE-627)167919229 |w (DE-600)605680-5 |w (DE-576)015904954 |x 0737-9587 |7 nnns |
| 773 | 1 | 8 | |g volume:93 |g year:2015 |g number:2 |g pages:127-135 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.critrevonc.2014.07.005 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25139841 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 93 |j 2015 |e 2 |h 127-135 | ||